A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
Leiserson et al.
PLOS ONE
December 2018
Authors and Affiliates
Leiserson MDM1,2, Syrgkanis V1, Gilson A1, Dudik M3, Gillett S1, Chayes J1,3, Borgs C1, Bajorin DF4,5, Rosenberg JE4, Funt S4,5, Snyder A4,6, Mackey L1; 1
Microsoft Research New England, Cambridge, MA, United States of America.
2
University of Maryland, College Park, Department of Computer Science, College Park, MD, United States of America.
3
Microsoft Research New York, New York, NY, United States of America.
4
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
5
Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America.
6
Adaptive Biotechnologies, Seattle, WA, United States of America